Patent · US Active

Compounds and methods for the targeted degradation of androgen receptor

US11883393B2 · kind B2 · utility

2Cited by

23References

4Claims

0Family size

Assignee

Arvinas Operations, Inc. · US

Inventors

Lawrence B. Snyder · Killingworth, US
Hanqing Dong · Madison, US

Key dates

Filing date	Dec 18, 2020
Grant date	Jan 30, 2024
Priority date	—
Expiry date	Aug 17, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.